+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of SAB-142 in people with Stage 3 New Onset Type 1 Diabetes. This Phase 2b study is designed as a randomized, double-blind, placebo-controlled trial to compare high and low doses of SAB-142 against a placebo. The study aims to better understand how SAB-142 may delay the progression of this condition in patients aged 5 to 40 years. The study includes three parts Part A is an open-label, parallel group phase Part B is a double-blind, placebo-controlled phase where participants receive either SAB-142 or placebo and Part C is a long-term follow-up phase assessing efficacy and safety, where participants may continue their assigned treatment or switch from placebo to active drug. Participants receive doses according to their assigned group, and dosing schedules follow the studys protocol across these phases. Participants will undergo several assessments including mixed meal tolerance tests to measure C-peptide levels, blood tests for HbA1c and autoantibodies, and continuous glucose monitoring to track blood sugar levels over time. Safety is monitored by recording adverse events throughout the study. Follow-up evaluations continue up to 24 months to assess long-term effects, with multiple visits scheduled for tests and sample collection to monitor disease progression and treatment impact.

Age: 5Years - 40YearsAll GendersPhase 2
68 locations